Showing 1661-1670 of 4063 results for "".
- Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-orion-1-phase-2-results-for-nyxol-in-clinical-ophthalmology/2478779/Ocuphire Pharma announced that results from its ORION-1 phase 2 clinical trial evaluating the safety and efficacy of Nyxol in glaucoma and presbyopia have been published in Clinical Ophthalmology. The paper, titled “Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil
- Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-plans-for-ncx-4251-phase-2-trial-in-blepharitis/2478408/Nicox SA announced that the upcoming Mississippi phase 2 trial of its second clinical candidate, NCX 4251 0.1%, will be focused on acute exacerbations of blepharitis. If successful in meeting the primary endpoint for blepharitis previously agreed upon with the FDA, the trial could represent the f
- Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-completes-enrollment-in-phase-2-clinical-trial-for-dry-eye-disease/2478192/Neuroptika announced completion of enrollment in a phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease. NRO-1 is a novel therapeutic with the potential to regenerate corneal nerves in ophthalmic diseases. “We are pleased to com
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenavahttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-for-norse-2-study-of-lytenava/2477982/Outlook Therapeutics announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. “We are extremely grateful to the patients and medical staff
- Medicel Launches First 2-in-1 Lens Injection Systemhttps://modernod.com/news/medicel-launches-first-2-in-1-lens-injection-system/2476740/Medicel says it has launched the world’s first 100% 2-in-1 lens injector, the Accuject Dual. The new injector enables surgeons to operate either in push or screw mode, allowing more control. Unlike competitor dual-mode injectors on the market that are 50% push and 50% screw, the Accuject
- Nicox Announces Completes Enrollment in NCX 470 Phase 2 Clinical Studyhttps://modernod.com/news/nicox-announces-completion-of-enrollment-in-ncx-470-phase-2-clinical-study-with-topline-results-on-track-for-early-4q-2019/2476734/Nicox SA announced that it has completed enrollment of patients in its multicenter, phase 2 clinical study evaluating NCX 470 nitric oxide (NO)-donating bimatoprost analog being tested in patients with open-angle glaucoma or ocular hypertension for its ability to lower IOP. This study is a head-t
- Aura Biosciences Presents Interim Phase 1b/2 Data at ASRShttps://modernod.com/news/aura-biosciences-presents-interim-phase-1b-2-data-at-asrs/2479994/Aura Biosciences presented interim data from an open-label phase 1b/2 study of its lead program, light-activated AU-011 for the treatment of primary choroidal melanoma, at the 36th annual American Society of Retina Specialists (ASRS) meeting in Vancouver, Canada. The findings were presented by Am
- Ocuphire Completes Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopiahttps://modernod.com/news/ocuphire-completes-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-combination-with-low-dose-pilocarpine-for-treatment-of-presbyopia/2479197/Ocuphire Pharma announced that it has completed enrollment in the VEGA-1 phase 2 clinical trial (
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t